JP2004517046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517046A5 JP2004517046A5 JP2002522936A JP2002522936A JP2004517046A5 JP 2004517046 A5 JP2004517046 A5 JP 2004517046A5 JP 2002522936 A JP2002522936 A JP 2002522936A JP 2002522936 A JP2002522936 A JP 2002522936A JP 2004517046 A5 JP2004517046 A5 JP 2004517046A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- channel
- pharmaceutical composition
- individual
- channel activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091006146 Channels Proteins 0.000 claims 36
- 239000003795 chemical substances by application Substances 0.000 claims 31
- 201000001880 Sexual dysfunction Diseases 0.000 claims 22
- 231100000872 sexual dysfunction Toxicity 0.000 claims 22
- 230000000694 effects Effects 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 13
- 210000004392 genitalia Anatomy 0.000 claims 8
- 210000002460 smooth muscle Anatomy 0.000 claims 8
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 6
- 238000004458 analytical method Methods 0.000 claims 6
- 201000001881 impotence Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 238000010171 animal model Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- -1 calcium-activated potassium Chemical class 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0021487.4A GB0021487D0 (en) | 2000-09-01 | 2000-09-01 | Pharmaceutical |
| PCT/IB2001/001525 WO2002017963A2 (en) | 2000-09-01 | 2001-08-24 | Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004517046A JP2004517046A (ja) | 2004-06-10 |
| JP2004517046A5 true JP2004517046A5 (no) | 2005-04-07 |
Family
ID=9898666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002522936A Withdrawn JP2004517046A (ja) | 2000-09-01 | 2001-08-24 | 医薬 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1313507A2 (no) |
| JP (1) | JP2004517046A (no) |
| AU (1) | AU2001282377A1 (no) |
| CA (1) | CA2420852A1 (no) |
| GB (1) | GB0021487D0 (no) |
| WO (1) | WO2002017963A2 (no) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7258850B2 (en) * | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
| NO20031157L (no) * | 2002-03-18 | 2003-09-19 | Jenapharm Gmbh | Fremgangsmåte for å identifisere en farmasöytisk aktiv forbindelse for behandling av en tilstand forårsaket av forandret ekspresjon avinsulinreseptoren |
| ES2222831B2 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2276466T3 (es) * | 1997-07-15 | 2007-06-16 | Astrazeneca Uk Limited | Polipeptido humano leucocitico del canal de potasio activado por calcio. |
| CA2349616A1 (en) * | 1998-12-04 | 2000-06-15 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| US6803375B1 (en) * | 2000-01-06 | 2004-10-12 | The Regents Of The University Of California | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto |
| EP1251840A2 (en) * | 2000-01-26 | 2002-10-30 | Cedars-Sinai Medical Center | Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
-
2000
- 2000-09-01 GB GBGB0021487.4A patent/GB0021487D0/en not_active Ceased
-
2001
- 2001-08-24 AU AU2001282377A patent/AU2001282377A1/en not_active Abandoned
- 2001-08-24 EP EP01960993A patent/EP1313507A2/en not_active Withdrawn
- 2001-08-24 CA CA002420852A patent/CA2420852A1/en not_active Abandoned
- 2001-08-24 WO PCT/IB2001/001525 patent/WO2002017963A2/en not_active Application Discontinuation
- 2001-08-24 JP JP2002522936A patent/JP2004517046A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL343755A1 (en) | Pharmacological composition, application of an agent in production of a drug, method of therapeutically treating female patients, testing method in order to identify said agent, method of identifying said agend, diagnosing method, diagnostic composition, animal model for use in identification of said agent and method of obtaining a drug | |
| RU2012147597A (ru) | Биомаркеры для ингибиторов mdm2, использующиеся для лечения заболевания | |
| Meredith et al. | Immune treatments for alcohol use disorder: A translational framework | |
| Pautassi et al. | Early maternal separation affects ethanol-induced conditioning in a nor-BNI insensitive manner, but does not alter ethanol-induced locomotor activity | |
| Weydt et al. | Clinical trials in spinal and bulbar muscular atrophy—past, present, and future | |
| Pairis-Garcia et al. | Behavioural evaluation of analgesic efficacy for pain mitigation in lame sows | |
| Kodippili et al. | Nitric oxide‐dependent attenuation of noradrenaline‐induced vasoconstriction is impaired in the canine model of Duchenne muscular dystrophy | |
| McDonald et al. | Enhanced cell death in hippocampus and emergence of cognitive impairments following a localized mini‐stroke in hippocampus if preceded by a previous episode of acute stress | |
| Hartwig et al. | Characterization and opioid modulation of inflammatory temporomandibular joint pain in the rat | |
| JP2004517046A5 (no) | ||
| Potter et al. | Effects of renal clearance on plasma concentrations of homovanillic acid: methodologic cautions | |
| Galaj et al. | Blockade of muscarinic acetylcholine receptors in the ventral tegmental area blocks the acquisition of reward-related learning | |
| Perry et al. | Comparison of three CIDR based fixed-time AI protocols for beef heifers | |
| Buffalari et al. | Cocaine self-administration and extinction alter medullary noradrenergic and limbic forebrain cFos responses to acute, noncontingent cocaine injections in adult rats | |
| Czyrak et al. | Antidepressant activity of S-adenosyl-L-methionine in mice and rats | |
| Christensen et al. | Chronic prenatal exposure to paroxetine (Paxil) and cognitive development of mice offspring | |
| Cheng et al. | 22 Evaluation of Current US Swine Selection Indexes and Indexes Designed for Chinese Pork Production. | |
| Saito et al. | Rabbit syphilis diagnosed clinically in household rabbits | |
| Suga et al. | Intensive treatment of a captive bornean elephant (Elephas maximus borneensis) infected with Mycobacterium caprae in Japan | |
| Benešová et al. | Brain maldevelopment and neurobehavioural deviations in adult rats treated neonatally with indomethacin | |
| Sheldon et al. | Butorphanol-Azaperone-Medetomidine Is as Safe and Effective as Nalbuphine-Azaperone-Medetomidine for Immobilization of Juvenile American Black Bears (Ursus americanus) | |
| Fregoso-Aguilar et al. | The differential effect of haloperidol and repetitive induction on four immobility responses in mouse and guinea pig | |
| Koziol | In vitro efficacy of anti-protozoal compounds against Tritrichomonas foetus | |
| Di Cesare | CLASSICAL AND POPULATION PHARMACOKINETICS OF ANTIMICROBIALS, SEDATIVES AND ANAESTHETICS IN VETERINARY MEDICINE | |
| Koss et al. | Pharmacological characterization of a noninvasive, chronic, experimental dog model of nasal congestion |